IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour
- PMID: 25759018
- DOI: 10.1016/j.ccell.2015.02.013
IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour
Abstract
There is a pressing need to develop novel, mechanism-based therapeutic approaches that can be used to improve therapies for genetically defined tumor subtypes. Chan and colleagues have demonstrated recently that BCL-2 inhibitors can target IDH1/2 mutant cancers through a mutant-specific dependency in metabolic regulation.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment on
-
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19. Nat Med. 2015. PMID: 25599133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous